Results 91 to 100 of about 36,987 (240)

PB1936: IDENTIFYING INEQUITIES IN SUPPORT - GLOBAL SURVEY OF PATIENT ORGANISATIONS DELIVERING SUPPORT SERVICES FOR CLL PATIENTS

open access: yesHemaSphere, 2023
Deborah Baker   +17 more
doaj   +1 more source

Reinke's Edema: From the Operating Theater to Office‐Based Blue Laser Treatment

open access: yesThe Laryngoscope, EarlyView.
In this retrospective study, 52 patients with Reinke's edema treated with office‐based 445‐nm blue laser were compared with a historical cohort of 40 patients treated by microlaryngoscopy under general anesthesia. Office‐based treatment was associated with significant improvement in Voice Handicap Index‐10 scores (15.0–2.0; p < 0.001) and complete ...
Francesco Mora   +5 more
wiley   +1 more source

Disease-specific complications of chronic lymphocytic leukemia in binet stage a patients [PDF]

open access: yes, 2012
Disease-specific Complications of Chronic Lymphocytic Leukemia in Binet Stage A Patients: Analysis of Immunodeficiency, Autoimmune Constellations and Infections in the CLL1-Protocol.
Kwag, Doo Young
core   +1 more source

PB2673: EXPERIENCES AND VIEWS OF LEUKEMIA CARERS: A GLOBAL SURVEY

open access: yesHemaSphere, 2023
Samantha Nier   +11 more
doaj   +1 more source

Linking SLAMF1 to autophagy and sensitivity to therapy in chronic lymphocytic leukemia

open access: yesMolecular & Cellular Oncology, 2018
We recently reported that expression of the costimulatory molecule and microbial sensor SLAMF1 (signaling lymphocytic activation molecule family 1, also known as CD150) is lost in chronic lymphocytic leukemia (CLL) patients characterized by a shorter ...
Cinzia Bologna, Silvia Deaglio
doaj   +1 more source

CLL cells

open access: yes, 2021
ROR1 – a receptor tyrosine kinase – is overexpressed in CLL. Ibrutinib, a Bruton's tyrosine kinase inhibitor, is clinically effective in CLL but patients may develop resistance. We evaluated the effect of an ROR1 inhibitor, KAN0441571C, in CLL cells from
Schultz, Johan   +29 more
core   +1 more source

In‐frame variants in TP53 gene identified in adult leukemia samples are predominantly deleterious: a study of the TP53 Network of Education and Research Initiative on CLL

open access: yesThe Journal of Pathology, EarlyView.
Abstract The prognostic and predictive impact of TP53 variants in leukemia led to their inclusion in diagnostic and treatment guidelines, increasing the demand for rapid, reliable laboratory analysis, interpretation, and reporting. While most TP53 variants identified in tumor samples can be interpreted using data from large‐scale functional studies ...
Šárka Pavlová   +28 more
wiley   +1 more source

Polyserositis as an Initial Manifestation of Chronic Lymphocytic Lymphoma

open access: yesIndian Journal of Medical Specialities
Chronic lymphocytic lymphoma (CLL) is a lymphoproliferative malignancy characterized by the generation and accumulation of CD5+ monoclonal B-cell lymphocytes, which are physically mature lymphocytes with aberrant immunological activity.
Sunita Aggarwal   +7 more
doaj   +1 more source

Management of CLL in the elderly

open access: yesAnnals of Oncology, 2017
Management of CLL in the ...
CUNEO, Antonio, Foã , R.
openaire   +4 more sources

Home - About - Disclaimer - Privacy